Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

被引：0

作者：

E Van Cutsem

C-P Li

E Nowara

G Aprile

M Moore

I Federowicz

J-L Van Laethem

C Hsu

C K Tham

S M Stemmer

R Lipp

A Zeaiter

A Fittipaldo

Z Csutor

B Klughammer

X Meng

T Ciuleanu

机构：

[1] Gastroenterology/Digestive Oncology,Division of Gastroenterology, Department of Medicine

[2] University Hospitals Leuven and KU Leuven,Department of Medical Oncology

[3] Taipei Veterans General Hospital,Division of Medical Oncology and Hematology

[4] National Yang-Ming University School of Medicine,Department of Gastroenterology

[5] Centrum Onkologii—Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach,GI Cancer Unit

[6] ul. Wybrzeże Armii Krajowej 15,Department of Medical Oncology

[7] University Hospital of Udine,undefined

[8] Princess Margaret Hospital,undefined

[9] NZOZ Magodent,undefined

[10] Erasme University Hospital-ULB-Brussels,undefined

[11] National Taiwan University Hospital,undefined

[12] National Cancer Center Singapore,undefined

[13] Institute of Oncology,undefined

[14] Davidoff Center,undefined

[15] Rabin Medical Center,undefined

[16] GermanOncology GmbH,undefined

[17] Roche Products Ltd,undefined

[18] F. Hoffmann-La Roche,undefined

[19] PD Biostatistics,undefined

[20] Roche,undefined

[21] Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu,undefined

来源：

British Journal of Cancer | 2014年 / 111卷

关键词：

pancreatic cancer; erlotinib; epidermal growth factor; oncology; dose; rash;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2067 / 2075

页数：8

共 341 条

[21] Valladares-Ayerbes M(2003)Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis Int J Mol Med 11 305-undefined
[22] Pericay C(2009)Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 2231-undefined
[23] Safont MJ(2009)Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer New Eng J Med 360 1408-undefined
[24] Mendez MJ(2012)Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study J Clin Oncol 30 2861-undefined
[25] Irigoyen A(2009)Rash as a marker for efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study J Clin Oncol 27 Abstract 4532-undefined
[26] Arrivi A(2007)Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 3913-undefined
[27] Sastre J(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-undefined
[28] Díaz-Rubio E(undefined)undefined undefined undefined undefined-undefined
[29] Buges C(undefined)undefined undefined undefined undefined-undefined
[30] Marti AM(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 4 5 6 7 8 9 10 →